

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

InVivoMab polyclonal Syrian hamster IgG

RRID:AB_1107782

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0087, RRID:AB_1107782)

Antibody Information

URL: http://antibodyregistry.org/AB_1107782

Proper Citation: (Bio X Cell Cat# BE0087, RRID:AB_1107782)

Host Organism: syrian hamster

Clonality: polyclonal

Antibody Name: InVivoMab polyclonal Syrian hamster IgG

Description: This polyclonal targets

Antibody ID: AB_1107782

Vendor: Bio X Cell

Catalog Number: BE0087

Alternative Catalog Numbers: BE0087-1MG, BE0087-5MG, BE0087-100MG, BE0087-50MG, BE0087-25MG

Record Creation Time: 20260114T192933+0000

Record Last Update: 20260225T232021+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMab polyclonal Syrian hamster IgG.

No alerts have been found for InVivoMab polyclonal Syrian hamster IgG.

Data and Source Information

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.

Blanchard L, et al. (2025) Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade. *Cell reports. Medicine*, 6(6), 102141.

Cho NW, et al. (2025) T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNF? *Inflammation. Cancer immunology research*, 13(2), 229.

He C, et al. (2024) UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. *Molecular cell*, 84(6), 1120.

Mahadevan KK, et al. (2024) Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. *Science (New York, N.Y.)*, 384(6703), eadh4567.

Beck JD, et al. (2024) Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers. *Cancer cell*.

You S, et al. (2024) Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity. *Cancer cell*, 42(8), 1415.

Gaglia G, et al. (2023) Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma. *Cancer cell*, 41(5), 871.

Yam AO, et al. (2023) Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy. *Cancer research*, 83(8), 1315.

Hailemichael Y, et al. (2022) Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. *Cancer cell*, 40(5), 509.

Shan Z, et al. (2021) Chitinase 3-like-1 contributes to acetaminophen-induced liver injury by promoting hepatic platelet recruitment. *eLife*, 10.

Burger ML, et al. (2021) Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. *Cell*, 184(19), 4996.

Kurtulus S, et al. (2019) Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells. *Immunity*, 50(1), 181.

Choi H, et al. (2019) Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. *Cell reports*, 27(3), 806.

Perrot I, et al. (2019) Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. *Cell reports*, 27(8), 2411.

Su W, et al. (2019) The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. *Cancer cell*, 36(2), 139.

Wei SC, et al. (2017) Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. *Cell*, 170(6), 1120.

Saha D, et al. (2017) Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. *Cancer cell*, 32(2), 253.